Scotiabank initiated coverage on Exact Sciences with a new price target
$EXAS
Medical Specialities
Health Care
Scotiabank initiated coverage of Exact Sciences with a rating of Sector Outperform and set a new price target of $70.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/28/2024 | $75.00 | Overweight | Wells Fargo |
| 6/27/2024 | $70.00 | Sector Outperform | Scotiabank |
| 6/3/2024 | $75.00 | Buy | Jefferies |
| 1/2/2024 | $91.00 | Hold → Buy | The Benchmark Company |
| 12/14/2023 | $90.00 | Buy | Guggenheim |
| 12/13/2023 | $95.00 | Outperform | Wolfe Research |
| 10/10/2023 | $90.00 | Neutral → Overweight | Piper Sandler |
| 9/28/2023 | $83.00 | Outperform | Bernstein |
Delivered record revenue and cash flow, improved adjusted EBITDA, advanced pipeline Third quarter highlights Total third quarter revenue of $709 million, an increase of 13% on a reported and core revenue basis, including Screening revenue of $545 million and Precision Oncology revenue of $164 million Net loss was $38 million, adjusted EBITDA was $99 million, and adjusted EBITDA margin increased 500 basis points to 14% Operating cash flow was $139 million with free cash flow of $113 million Received FDA approval for the Cologuard Plus™ test, the Company's next-generation Cologuard® test Presented data showing potential of its blood-based colorectal cancer screening test, with sens
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2024 financial results after the close of the U.S. financial markets on November 5, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Third quarter 2024 webcast & conference call details Date: Tuesday, November 5, 2024 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 Inte
Reports record results, screened more than 1 million people with Cologuard®, raises adjusted EBITDA guidance Second quarter highlights Delivered total second quarter revenue of $699 million, an increase of 12%, or 13% on a core revenue basis, including Screening revenue of $532 million and Precision Oncology revenue of $168 million Screened more than 1 million people with Cologuard for the first time during a quarter and tested a record number of cancer patients with Oncotype DX® Advanced pipeline by generating evidence supporting molecular residual disease, multi-cancer screening, and blood-based colorectal cancer screening tests Maintains full-year 2024 revenue guidance and
4 - EXACT SCIENCES CORP (0001124140) (Issuer)
4 - EXACT SCIENCES CORP (0001124140) (Issuer)
4 - EXACT SCIENCES CORP (0001124140) (Issuer)
Financing Fuels the Company's Hypergrowth to Make Elevated Care Accessible to More Patients Petrovic's Appointment Positions Imperative Care for Long Term Success and Scale Imperative Care, Inc., a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the initial close of an oversubscribed Series E financing. The financing was led by Ally Bridge Group with participation from other existing investors, including D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital Management LP, Innovatus Capital Partners, LLC and Pura Vida Investments. The financing also incl
Exact Sciences (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024. Mr. Bloomer brings to Exact Sciences more than 15 years of finance and accounting experience. He previously held leadership positions at Baxter International and 3M, where he helped improve financial results, drove operational rigor, led strategic growth initiatives, played key roles in portfolio management, acquisitions, and divestitures, and set corporate strategy and vision. At Baxter, Mr. Bloomer led corporate financial planning, reporting, and analytics (FP&A) as vice president. Prior to t
In collaboration with The Blue Hat Foundation, "Box Out Colon Cancer" offers a timely spotlight on screening and prevention for the nation's #2 cancer-related killer1 Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with iconic pro basketball all-star and Kentucky legend Jamal Mashburn to introduce "Box Out Colon Cancer," in observance of Colorectal Cancer Awareness Month and the most exciting time in college basketball. This national educational campaign will encourage everyone 45 and older to screen for colon cancer – a disease affecting people of all races, genders, and ethnicities – in line with American Cancer Society reco
4 - EXACT SCIENCES CORP (0001124140) (Issuer)
Wells Fargo initiated coverage of Exact Sciences with a rating of Overweight and set a new price target of $75.00
Scotiabank initiated coverage of Exact Sciences with a rating of Sector Outperform and set a new price target of $70.00
Jefferies resumed coverage of Exact Sciences with a rating of Buy and set a new price target of $75.00
New evidence shows multi-biomarker class approach improved cancer detection, including in earlier stages when treatment may be more effective Modeling data estimate adding MCED testing to standard-of-care screening could reduce cancer mortality by 17% New analysis from DETECT-A study supports MCED testing as a complement to current guideline-recommended screening Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection (MCED) test. The results of a study evaluating a new multi-biomarker class approach showed improved sensitivit
Delivered record revenue and cash flow, improved adjusted EBITDA, advanced pipeline Third quarter highlights Total third quarter revenue of $709 million, an increase of 13% on a reported and core revenue basis, including Screening revenue of $545 million and Precision Oncology revenue of $164 million Net loss was $38 million, adjusted EBITDA was $99 million, and adjusted EBITDA margin increased 500 basis points to 14% Operating cash flow was $139 million with free cash flow of $113 million Received FDA approval for the Cologuard Plus™ test, the Company's next-generation Cologuard® test Presented data showing potential of its blood-based colorectal cancer screening test, with sens
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. Jefferies London Healthcare Conference, London Fireside chat on Tuesday, November 19, 2024 at 6:00 a.m. ET The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Colo
SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)
SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)
SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)
Analysts' ratings for Exact Sciences (NASDAQ:EXAS) over the last quarter vary from bullish to bearish, as provided by 8 analysts. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 2 2 0 0 0 2M Ago 0 0 0 0 0 3M Ago 3 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Exact Sciences, presenting an average target of $75.25, a high estimate of $85.00, and a low estimate of $70.00. A negative shift in sentiment is evident
Goldman Sachs analyst Matthew Sykes maintains Exact Sciences (NASDAQ:EXAS) with a Buy and lowers the price target from $88 to $75.
Evercore ISI Group analyst Vijay Kumar maintains Exact Sciences (NASDAQ:EXAS) with a Outperform and lowers the price target from $80 to $72.
10-Q - EXACT SCIENCES CORP (0001124140) (Filer)
8-K - EXACT SCIENCES CORP (0001124140) (Filer)
10-Q - EXACT SCIENCES CORP (0001124140) (Filer)